FDA Approves Cepheid Test for S. Aureas, MRSA | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid today announced it has received clearance from the US Food and Drug Administration to market its Xpert SA Nasal Complete.

The test is the only molecular diagnostic product designed for the detection and differentiation of Staphylococcus aureas and Methicillin-resistant Staphylococccus aureus colonization in under one hour, Cepheid said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.